Aptose Biosciences Files 8-K Report
Ticker: APTOF · Form: 8-K · Filed: Oct 16, 2025 · CIK: 882361
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Oct 16, 2025, covering Reg FD and financials. Nothing major revealed yet.
AI Summary
On October 16, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.
Why It Matters
This 8-K filing provides important updates on Aptose Biosciences' regulatory disclosures and financial information, which are crucial for investors to assess the company's current standing.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on disclosures and exhibits, not indicating any immediate significant operational or financial changes.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc. (company) — Former company name
- October 16, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is for Regulation FD disclosures and to report financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 16, 2025.
What industry does Aptose Biosciences Inc. operate in?
Aptose Biosciences Inc. operates in the Biological Products (No Diagnostic Substances) sector.
What were some of Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which country is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-10-16 07:45:28
Filing Documents
- f8k_101525.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-25-006472.txt ( ) — 221KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_101525_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 16, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated October 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: October 16, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer